Translumina
Medical device company focused on interventional cardiovascular devices. Operates manufacturing facilities in Germany, the Netherlands and India, develops and commercializes coronary stents, balloon catheters and drug-coated balloon technologies, conducts multi-country clinical trials and maintains in-house R&D, quality and regulatory functions to support global market registrations.
Industries
Nr. of Employees
small (1-50)
Translumina
Neue Rottenburger Strasse 50, D-72379 Hechingen, Germany
Products
Drug-eluting stent systems (sirolimus-eluting; polymer-free and biodegradable polymer variants)
Coronary stent systems using metallic platforms with engineered microporous surfaces and controlled drug-release coatings (abluminal and full-surface options) designed for implantable coronary interventions and long-term safety evaluation.
Drug-coated balloon platforms (paclitaxel and other drug matrices)
Balloon catheters with surface-applied drug matrices and carrier layers designed for homogeneous drug transfer to the vessel wall using a leave-nothing-behind approach; manufacturing features to minimise drug loss during transit and allow multiple inflation drug delivery.
PTCA balloon catheters (semi-compliant and non-compliant)
PTCA balloon catheters engineered for lesion crossing, deliverability and controlled post-dilatation with options for high-rated burst pressure, low-profile tips, hydrophilic coatings and folding technologies to improve trackability and decrease friction.
Vascular access and ancillary interventional accessories
Portfolio of vascular access devices and procedural accessories to support interventional workflows and device procedures.
Drug-eluting stent systems (sirolimus-eluting; polymer-free and biodegradable polymer variants)
Coronary stent systems using metallic platforms with engineered microporous surfaces and controlled drug-release coatings (abluminal and full-surface options) designed for implantable coronary interventions and long-term safety evaluation.
Drug-coated balloon platforms (paclitaxel and other drug matrices)
Balloon catheters with surface-applied drug matrices and carrier layers designed for homogeneous drug transfer to the vessel wall using a leave-nothing-behind approach; manufacturing features to minimise drug loss during transit and allow multiple inflation drug delivery.
PTCA balloon catheters (semi-compliant and non-compliant)
PTCA balloon catheters engineered for lesion crossing, deliverability and controlled post-dilatation with options for high-rated burst pressure, low-profile tips, hydrophilic coatings and folding technologies to improve trackability and decrease friction.
Vascular access and ancillary interventional accessories
Portfolio of vascular access devices and procedural accessories to support interventional workflows and device procedures.
Services
Commercialization and distribution support for interventional cardiovascular devices across multiple international markets.
Commercialization and distribution support for interventional cardiovascular devices across multiple international markets.
Expertise Areas
- Interventional cardiology device manufacturing
- Clinical trial management, registries and long-term outcome analysis
- Drug-delivery platform development for vascular devices (stents and DCBs)
- Materials and surface engineering for implantable vascular devices
Key Technologies
- Microporous surface engineering (sandblasting)
- Abluminal drug coating and unidirectional release
- Biodegradable polymer drug matrices (PLA)
- Polymer-free drug matrices and dual-drug carrier approaches
News & Updates
Announcement of initiation of direct operations in the UAE for expanded regional presence.
Acquisition to expand technology portfolio and access to next-generation drug-coated balloon and balloon platform technologies.
Company references multiple stent platforms supported by long-term clinical data (including 10-year analyses) reporting favorable safety and efficacy metrics and comparative outcome analyses versus historical comparator stents.
Operation of manufacturing facilities and clean-room capacity in Germany, the Netherlands and India to support product manufacture and supply.
Announcement of initiation of direct operations in the UAE for expanded regional presence.
Acquisition to expand technology portfolio and access to next-generation drug-coated balloon and balloon platform technologies.
Company references multiple stent platforms supported by long-term clinical data (including 10-year analyses) reporting favorable safety and efficacy metrics and comparative outcome analyses versus historical comparator stents.
Operation of manufacturing facilities and clean-room capacity in Germany, the Netherlands and India to support product manufacture and supply.